30 closest matches · ranked by relevance
Hemophagocytic Lymphohistiocytosis
Primary: Mean Serum Concentration of Inflammatory Biomarker - C-X-C Chemokine Ligand 10 (CXCL10) — 5040.638; 454.392 picogram/milliliter (pg/mL)
Hemophagocytic Lymphohistiocytoses
Primary: Mean Serum Concentration of Inflammatory Biomarker - C-X-C Chemokine Ligand 10 (CXCL10) — 2079.286; 15197.143 picogram/milliliter (pg/mL)
Primary Haemophagocytic Lymphohistiocytosis
Primary: Overall Response Rate (ORR) Second Line — 63.0 percentage of participants — p=0.0134
Leukemia
Primary: Number of Participants With a Response to Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With…
Primary Hemophagocytic Lymphohistiocytosis
Primary: Overall Response at Week 8 or End of Treatment (if Earlier) — 62.9; 50.0; 73.7 Percentage of participants — p=0.0053
Hemophagocytic Lymphohistiocytosis
Primary: Overall Survival — 25 Participants
Hemophagocytic Lymphohistiocytosis · Chronic Active Epstein-Barr Virus Infection · Chronic Granulomatous Disease
Primary: Percentage of Participants With Overall Survival (OS) — 80.4; 66.7 percentage of participants
Hemophagocytic Syndrome (HPS)
Primary: Overall Survival at 2 Months — 6 Participants
Hemophagocytic Lymphohistiocytosis
Primary: Number of Participants With Adverse Event (AE) — 37; 12; 7 Participants
Acute Myeloid Leukemia · Acute Lymphocytic Leukemia · Myelodysplasia
Primary: One-year Survival — 50 percentage of participants
Hemophagocytic Lymphohistiocytosis · X-Linked Lymphoproliferative Disorders · Chediak-Higashi Syndrome
Primary: Number of Subjects With Mixed Chimerism — 3; 8; 4 participants
Adrenoleukodystrophy · Metachromatic Leukodystrophy · Globoid Cell Leukodystrophy
Primary: Number of Patients With Donor Cell Engraftment — 26 Participants
Macrophage Activation Syndrome · Lymphohistiocytosis, Hemophagocytic · Arthritis, Juvenile
Primary: Incidence, Severity, Causality, and Outcomes of AEs (Serious and Nonserious) — 13; 6; 2; 10 Participants
Primary Hemophagocytic Lymphohistiocytosis
Primary: Permanent Discontinuation of Study Drug Due to Emapalumab-related Adverse Event — 0 Participants
Lysosomal Storage Disease · Peroxisomal Disorder
Primary: Donor (Allogeneic) Hematopoietic Engraftment — 1 participants
Hodgkin Disease · Non Hodgkin Lymphoma · Lymphoepithelioma
Primary: Dose Limiting Toxicity (DLT) Rate by the NCI Common Toxicity Criteria (CTCAE) v2.0 and the Method of Przepiorka et al (Protocol Appendix I) — 0; 0; 0; 0 proportion of…
Hematological Malignancies
Primary: Overall Survival at 6 Months Post-transplant in Patients Receiving a Partially-matched Related Donor Allogeneic Transplant After Reduced-intensity Conditioning — 22…
Juvenile Myelomonocytic Leukemia
Primary: Determine Probability of Long-term Disease Free Survival in JMML — 67 Percentage of participants
Myeloablative Conditioning · HLA-mismatched Bone Marrow Transplantation · Graft Survival
Primary: Cumulative Incidence of Non-relapse Mortality — 0 percent
Leukemia · Lymphoma
Primary: Number of Transplant Recipients With Successful Engraftment — 70 Participants
Primary Immune Deficiency Disorder · Hematopoietic Stem Cell Transplantation
Primary: Overall Survival — 86; 86; 87 percentage of survival probability — p=0.95
Acute Leukaemia · Chronic Disease · Leukemia
Primary: Number of High Risk Pediatric Patients With Successful Sustained Donor Engraftments — 16; 18; 10 participants
Leukemia, Myeloid, Acute · Leukemia, Lymphoblastic, Acute · Leukemia, Myelocytic, Chronic
Primary: Overall Recipient Survival at 6-month Post-relapse of Disease — 0; 4 participants
Hematopoietic/Lymphoid Cancer
Primary: Count of Participants That Experience 1 Year Relapse Free Survival After Undergoing Hematopoietic Stem Cell Transplantation (HSCT) Using the Thomas Jefferson University…
EBV-induced Lymphomas · EBV-associated Malignancies · Transplant Patients With EBV Viremia at High Risk for Developing a Recurrent EBV Lymphoma
Primary: Objective Response Rate (ORR) — 68.0; 50.0; 16.0; 14.3 Percentage of participants
Macrophage Activation Syndrome · Secondary Hemophagocytic Lymphohistiocytosis · Still Disease
Primary: Proportion of Subjects With Complete Response (CR) at Week 8 After First Administration of Emapalumab — 11; 4 Participants
Leukemia · Lymphoma · Multiple Myeloma and Plasma Cell Neoplasm
Primary: Complete Remission Rate — 8; 6 Participants
Acute Myeloid Leukemia · Acute Lymphoblastic Leukemia · Biphenotypic Acute Leukemia
Primary: Disease Free Survival — 70.6 percentage of participants — p=0.002
Acute Myeloid Leukemia · Myelodysplastic Syndrome
Primary: Number of Subjects With Unacceptable Toxicity — 1 Participants
Mucopolysaccharidosis I · Mucopolysaccharidosis VI · Mannosidosis
Primary: Mean Percentage of Donor Cells in Study Population (Chimerism). — 85.8; 73.2; 84.6; 81.1 Percentage